Raymond James Financial Upgrades Teleflex (NYSE:TFX) to Outperform

Teleflex (NYSE:TFX) was upgraded by equities research analysts at Raymond James Financial from a “market perform” rating to an “outperform” rating in a research report issued on Friday, Marketbeat reports. The firm presently has a $128.00 price target on the medical technology company’s stock. Raymond James Financial’s price objective would indicate a potential upside of 10.13% from the company’s previous close.

A number of other equities research analysts also recently weighed in on TFX. Needham & Company LLC raised their target price on Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Truist Financial upped their price objective on Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a research report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research report on Monday, December 29th. Zacks Research downgraded Teleflex from a “hold” rating to a “strong sell” rating in a research note on Monday, March 2nd. Finally, Wells Fargo & Company increased their target price on shares of Teleflex from $116.00 to $130.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Teleflex has a consensus rating of “Hold” and an average target price of $139.00.

Teleflex Price Performance

TFX stock opened at $116.23 on Friday. The company’s 50-day moving average price is $109.07 and its two-hundred day moving average price is $116.67. The firm has a market cap of $5.14 billion, a P/E ratio of -5.66, a P/E/G ratio of 0.72 and a beta of 0.87. The company has a quick ratio of 2.01, a current ratio of 2.54 and a debt-to-equity ratio of 0.81. Teleflex has a 12 month low of $100.18 and a 12 month high of $141.91.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, February 26th. The medical technology company reported $1.93 earnings per share for the quarter, missing analysts’ consensus estimates of $3.73 by ($1.80). The firm had revenue of $569.00 million for the quarter, compared to the consensus estimate of $912.57 million. Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.The business’s revenue was down 28.5% on a year-over-year basis. During the same period last year, the company posted $3.89 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, analysts anticipate that Teleflex will post 13.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Teleflex

A number of institutional investors and hedge funds have recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Teleflex by 57.9% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 77 shares in the last quarter. Banque Cantonale Vaudoise raised its holdings in Teleflex by 82.5% in the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after buying an additional 113 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in Teleflex by 248.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after buying an additional 199 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Teleflex during the 3rd quarter worth approximately $35,000. Finally, V Square Quantitative Management LLC bought a new stake in Teleflex during the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 95.62% of the company’s stock.

Trending Headlines about Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Irenic, a ~2% Teleflex shareholder, called for the Board to form a strategic-review sub‑committee with independent directors and to engage potential acquirers — a direct catalyst for takeover interest that can lift valuation expectations. Irenic Comments on Teleflex’s Announcement That It Is Open to Strategic Alternatives
• Positive Sentiment: Raymond James upgraded Teleflex from Market Perform to Outperform with a $128 price target, signaling analyst conviction that there’s upside from either operational improvement or strategic outcomes. Raymond James upgrade coverage
• Neutral Sentiment: Teleflex issued a formal statement reiterating its commitment to value‑maximizing strategies and said management met with Irenic on March 19 to understand their views — indicates engagement but not yet a formal review process. Teleflex Reiterates Commitment to Value‑Maximizing Strategies and Strong Execution
• Neutral Sentiment: Other shareholders and outlets are echoing calls for Teleflex to engage potential buyers, adding public pressure that could push the Board toward a more formal process. Teleflex shareholder urges company engage buyers
• Negative Sentiment: Teleflex pushed back, saying Irenic falsely claimed the company was not open to buyout offers — the public dispute raises governance/uncertainty risk and could deter some bidders or prolong a process. Teleflex says Irenic falsely claimed company was not open for buyout offers
• Negative Sentiment: Fundamentals remain a headwind: Teleflex reported a large recent earnings and revenue miss and guidance that reflects recovery needs — operational weakness could limit strategic options or depress standalone valuation until results improve.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.